Labcorp Holdings Inc. (LH)

FairStock Score: 50/100 — MIXED

Key Financials

Strengths

• Recurring, non-discretionary revenue from essential diagnostic testing with stable demand
• Meaningful free cash flow generation of $967M providing financial flexibility
• Diversified service portfolio across diagnostics and biopharma laboratory segments
• Low beta of 0.97 suggests stable, defensive business characteristics
• Large scale with 61,770 employees providing operational efficiency

Concerns

• Valuation is severely stretched at 25.1x P/E with only 5.12% ROCE—paying premium for mediocre capital returns
• Graham Number of $68.69 versus current price of $273.61 indicates 298% overvaluation with no margin of safety
• Deteriorating financial quality reflected in Piotroski F-Score of 5/9 and concerning Altman Z-Score of 2.39
• Excessive EV/EBITDA of 68.5x for a mature, slow-growth business with limited competitive advantages

AI Analysis

I've examined Labcorp with considerable skepticism. While the company operates in an essential, non-discretionary business—clinical laboratory diagnostics serve as the backbone of modern healthcare—the valuation tells a troubling story. At $273.61 per share, we're paying 25.1x earnings for a business generating mediocre returns: a 10.51% ROE and a deeply concerning 5.12% ROCE. These returns barely exceed the cost of capital, suggesting management hasn't deployed capital efficiently despite decades of operation. The Graham Number of $68.69 indicates we're paying nearly four times intrinsic value—a 298% negative margin of safety. This is precisely the type of premium-priced mediocrity Graham would have avoided. The balance sheet shows moderate leverage at 0.76 D/E, and free cash flow of $966.6M is respectable, but the Piotroski F-Score of 5/9 signals deteriorating financial health. The EV/EBITDA of 68.5x is extraordinarily expensive for a mature, low-growth diagnostics business. Most concerning is the Altman Z-Score of 2.39, lurking in the grey zone—not distressed, but not comfortably solvent either. The business generates recurring revenue, true, but I'm unwilling to pay growth stock multiples for a slow-growth, capital-light business with uninspiring returns on invested capital. Quality businesses at fair prices beat fair businesses at quality prices—this is neither.

Bull Case

Labcorp's essential services and recurring revenue base provide stability during economic downturns, while consolidation in the diagnostics industry could enable margin expansion. Digital transformation and value-based care initiatives may unlock operational leverage and improve ROCE over time.

Bear Case

Continued valuation compression is likely as interest rates remain elevated and investors demand better capital efficiency. Market saturation, pricing pressure from insurance companies, and modest growth rates suggest the current premium valuation is unsustainable and vulnerable to significant repricing.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer